Giant Cell tumors (GCT) are benign tumors with potential for aggressive behavior and
capacity to metastasize. Although rarely lethal, benign bone tumors may be associated with …

Background: Primary and recurrent giant cell tumor of bone is typically benign; however,
rarely giant cell tumor of bone can undergo malignant transformation. Malignancy in giant …

Background: Recent clinical studies have suggested that denosumab is associated with
tumor response and reduced surgical morbidity in patients with giant-cell tumor of bone …

Background Surgical resection with curative intent for giant cell tumor of bone (GCTB) may
be associated with severe morbidity. This interim analysis evaluated reduction in surgical …

Giant cell tumor (GCT) of bone is a locally aggressive benign neoplasm that is associated
with a large biological spectrum ranging from latent benign to highly recurrent and …

Giant cell tumour of bone (GCTB) is an intermediate locally aggressive primary bone tumour,
occurring mostly at the meta-epiphysis of long bones. Overexpression of receptor activator of …

Abstract Purpose of Review Denosumab is an inhibitor of receptor activator of nuclear factor
kappa-B ligand (RANKL), and has emerged as an important novel therapy for skeletal …

Giant cell tumor of bone (GCTB) and desmoplastic fibroma (DF) are bone sarcomas with
intermediate malignant behavior and unpredictable prognosis. These locally aggressive …

The heterogeneity of sarcomas with regard to molecular genesis, histology, clinical
characteristics, and response to treatment makes management of these rare yet diverse …

Background Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive, rarely
metastazing bone tumor. This is a retrospective study evaluating a large series of GCTB …